Multi-cancer early detection – promise or reality?
While there has been significant progress in the development of these blood tests, hurdles remain including test sensitivity and false positives
Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
Multi-gene ctDNA profiling effectively matches patients with advanced cancer to targeted therapies
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
Translational research: from bytes to bedside
According to Prof. Serena Nik-Zainal, 2024 ESMO Translational Research Awardee it is important to change the mindset of the cancer community to embrace all the information available through genome research
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
How to interpret genomic testing results? ESMO recommendations to make reports easy to read
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
Incorporating ctDNA into clinical trial design
ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease